Share Forum - Discuss JSE shares and join the Investor Challenge

  S&P 500 Futures 2,125.45 +0.95 +0.04%   
  Nasdaq Futures 4,526.40 -2.35 -0.05%   
  US 30 18,232.02 -53.72 -0.29%   
  S&P 500 VIX 12.13 +0.02 +0.17%   
  DAX 11,815.01 -49.58 -0.42%   
  Nikkei 225 20,413.77 +149.36 +0.74%   

0700.HK  + 1.28% 158.80
NPSNY    +0.32% 154.60
BABA    -0.65% 93.27
MAIL.IL    -0.72% 24.70

AVL needs to go above R2.60

Sies Tannie, I have NPN shares...

Update : -

APN - PE 34
AVL - PE 55
NPN - PE 106
OCE - PE 18

Thanks Mr Bond. 

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)


DIVESTMENT OF PORTFOLIO OF BRANDED AND GENERIC PRODUCTS TO STRIDES ENTITIES

Aspen is pleased to announce that certain of its wholly owned Australian subsidiaries (collectively “Aspen
Australia”), have entered into an agreement with Strides (Australia) Pharma Pty Ltd (“Strides Australia”), a
company incorporated in Australia, in terms whereof Aspen Australia will divest to Strides Australia, a
portfolio of approximately 130 products for a consideration of approximately A$265 million (“the Australian
Transaction”).

The portfolio of products in the Australian Transaction comprises a generic pharmaceutical business
together with certain branded pharmaceutical assets. This portfolio recorded revenue of A$106 million and
a direct contribution to profit before tax of A$26 million for the year ended 30 June 2014.

In a separate transaction, Aspen Global Incorporated (“AGI”), a company incorporated in Mauritius, has
entered into an agreement with Strides Pharma Global Pte Limited (“Strides Singapore”), a company
incorporated in Singapore, in terms whereof AGI will divest to Strides Singapore, a portfolio of six branded
prescription products, for a consideration of approximately US$92 million. This portfolio recorded revenue
of US$12 million and a direct contribution to profit before tax of US$10 million for the year ended
30 June 2014.

Strides Australia and Strides Singapore are wholly owned subsidiaries of Strides Arcolab Limited (“Strides”),
a pharmaceutical company headquartered and publicly listed in India. Strides have a key focus on the
development and manufacture of IP-led, niche pharmaceuticals products.

These transactions form part of Aspen’s communicated strategic intent to focus attention in areas where
most value can be added and to lessen complexity.

The transactions are conditional upon, inter alia, the approval of the Australian Foreign Investments Review
Board.


Durban
21 May 2015

  S&P 500 Futures 2,118.45 -4.05 -0.19%   
  Nasdaq Futures 4,493.60 -11.90 -0.26%   
  US 30 18,285.40 -26.99 -0.15%   
  S&P 500 VIX 12.88 +0.03 +0.23%   
  DAX 11,848.47 -4.86 -0.04%   
  Nikkei 225 20,202.87 +6.31 +0.03%   

0700.HK -1.20% 156.70
NPSNY +0.79% 156.10
BABA  +2.82% 90.70
MAIL.IL -1.36% 24.71

the Consensus Forecasts is also nice.